Transgenic Group Inc. (TYO:2342)
220.00
+6.00 (2.80%)
Aug 6, 2026, 2:15 PM JST
Transgenic Group Revenue
In the fiscal year ending March 31, 2026, Transgenic Group had annual revenue of 13.17B JPY with 1.30% growth. Transgenic Group had revenue of 3.48B in the quarter ending March 31, 2026, with 8.79% growth.
Revenue
13.17B
Revenue Growth
+1.30%
P/S Ratio
0.27
Revenue / Employee
58.04M
Employees
227
Market Cap
3.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.17B | 169.00M | 1.30% |
| Mar 31, 2025 | 13.01B | -78.00M | -0.60% |
| Mar 31, 2024 | 13.08B | 1.65B | 14.47% |
| Mar 31, 2023 | 11.43B | -1.15B | -9.12% |
| Mar 31, 2022 | 12.58B | 1.53B | 13.85% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kohjin Bio | 4.94B |
| Soiken Holdings | 4.40B |
| Human Metabolome Technologies | 1.30B |
| Chiome Bioscience | 601.75M |
| D. Western Therapeutics Institute | 305.97M |
| Cyfuse Biomedical K.K. | 234.00M |
| Kringle Pharma | 73.00M |
| Ribomic | 3.00M |